Results 21 to 30 of about 354,322 (345)

MRI in multiple myeloma : a pictorial review of diagnostic and post-treatment findings [PDF]

, 2016
Magnetic resonance imaging (MRI) is increasingly being used in the diagnostic work-up of patients with multiple myeloma. Since 2014, MRI findings are included in the new diagnostic criteria proposed by the International Myeloma Working Group.
A Baur, A Baur-Melnyk, A Stabler, AR Padhani, AR Padhani, AR Padhani, AR Padhani, B Turkbey, BC Vande Berg, C Hayes, C Jakob, C Lavini, C Lin, C Messiou, C Nanni, CM Zechmann, D Smith, DM Koh, E Mena, F Alyas, FE Lecouvet, G Pratt, GP Schmidt, HE Daldrup-Link, J Caers, J Hillengass, J Hillengass, J Hillengass, JC Dutoit, JC Dutoit, JC Dutoit, JR Silva Jr, KL Verstraete, KL Verstraete, LA Moulopoulos, LM Shah, M Fenchel, M Horger, M Merz, MA Dimopoulos, MM Khoo, P Bannas, R Garcia-Figueiras, RA Kyle, S Nosas-Garcia, SL Giles, SV Rajkumar, SV Rajkumar, T Derlin, T Derlin, TM Moehler, Y Zha   +51 more
core   +2 more sources

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study

Cancer Medicine, 2022
Background Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use.
Man Shen, Jiajia Zhang, Ran Tang, Yuhao Wang, Xiaokai Zhan, Sibin Fan, Zhongxia Huang, Yuping Zhong, Xin Li   +8 more
doaj   +1 more source

Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation

Blood Cancer Journal, 2021
MYC upregulation is associated with multidrug refractory disease in patients with multiple myeloma (MM). We, isolated patient-derived MM cells with high MYC expression and discovered that NCOR2 was down-regulated in these cells.
Tomoaki Mori, Rakesh Verma, Rie Nakamoto-Matsubara, Ka Tat Siu, Cristina Panaroni, Keertik S. Fulzele, Kenta Mukaihara, Chukwuamaka Onyewadume, Allison Maebius, Hiroki Kato, Lai Ping Wong, Ruslan I. Sadreyev, David T. Scadden, Noopur S. Raje   +13 more
doaj   +1 more source

Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation [PDF]

, 2012
Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk ...
Baumann, Philipp, Bumeder, Irmgard, Hörauf, Natalie, Oduncu, Fuat S., Otto, Sven, Pautke, Christoph, Röhnisch, Tim, Schmidmaier, Ralf, Then, Cornelia, Tresckow, Emmo von   +9 more
core   +1 more source

Multiple myeloma and physical activity: a scoping review [PDF]

, 2015
Objectives: Multiple myeloma is the second most common haematological cancer. A growing body of literature is emerging that investigates the role physical activity plays in all stages of multiple myeloma (prevention and survivorship) and to date no ...
Fisher, A, Heinrich, M, McCourt, O, Paton, B, Smith, L, Wardle, J, Yong, K   +6 more
core   +1 more source

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Protein & Cell, 2018
Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of
Li Yang, Jing Chen, Xiaoyan Han, Enfan Zhang, Xi Huang, Xing Guo, Qingxiao Chen, Wenjun Wu, Gaofeng Zheng, Donghua He, Yi Zhao, Yang Yang, Jingsong He, Zhen Cai   +13 more
doaj   +1 more source

Multiple myeloma

Annals of Oncology, 2010
Multiple myeloma (MM) is the second most common hematological malignancy, with an incidence of 6/100,000 in Europe. Interactions between myeloma cells and the microenvironment are essential for MM cell survival. Better knowledge of disease biology has led to the introduction of novel agents for the management of myeloma patients.
Dimopoulos, M. A., Terpos, E.
openaire   +5 more sources

Phagocytic plasma cells in a patient with multiple myeloma [PDF]

, 1995
Phagocytosis of blood cells by malignant plasma cells in multiple myeloma is an extremely rare condition. Here we present a 39-year-old woman with multiple myeloma.
Hagemeijer, A. (Anne), Leeuw, K. (K.) de, Löwenberg, B. (Bob), Vanhagen, P.M. (P.)   +3 more
core   +1 more source

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

Experimental Hematology & Oncology, 2017
B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies.
Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu, Kenneth C. Anderson   +4 more
doaj   +1 more source

ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma

npj Precision Oncology, 2023
Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the ...
Sung-Soo Park, Jong Cheol Lee, Ja Min Byun, Gyucheol Choi, Kwan Hyun Kim, Sungwon Lim, David Dingli, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hwan Shin, Chang-Ki Min, Jamin Koo   +11 more
doaj   +1 more source